RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA -Primary endpoint DAS28-CRP change wk12 -2.06 to -2.12 (all doses) vs -1.69 PBO p<0.01 -ACR20/50/70 + CDAI LDA all improved vs PBO -hsCRP reduction across all dose arms -69% CDAI LDA by wk14 -wk 28 extension shows https://t.co/AMfmSded0D

A new MoA that does not meet it's primary endpoint in RA SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib ACR20 wk12 NOT significantly diff vs PBO ~48.5–61.8% across doses vs 52.3% PBO Secondary BALI 200 mg QD: ACR50: 36.9% vs 18.5% (nominal p=0.0179) Mechanistic https://t.co/hmZ93JisiO

#EULAR2026 OP0228 Is there “something in the air?” Data from US Market Scan: poor quality index was associated with increased risk of #SLE. Although causal inference cannot be deduced, seems an important environmental factor. To check air quality assoc with UV index @RheumNow https://t.co/1FOw7RDA9a

#EULAR2026 OP0166 In a phase III RCT in dermatomyositis, brepocitinib, first in class selective SyK-i and JAK1-i showed rapid meaningful improvement in cutaneous DM as early as Week 4 vs PBO. Exciting option and is under FDA Priority Review for approval @RheumNow #EULARBest https://t.co/9b0WurgBkN

Which ‘CAR’ to drive in #SLE? Comparison of #CD19 #CAR-T #allogenic vs #Autologous ➡️ comparing #molecular #responses from 2 #lupus studies N=12 Both improved cytokine signatures For #IFN & #neutrophils Results similar not identical ?either #POS0678 #EULAR2026 @RheumNow https://t.co/Lcpv3qJ6tU

Rheumatology Shortage Cliff in Australia & USA Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States. The Australian Rheumatology Association's 2025 Workforce Report warns that the nation faces a significant https://t.co/qVziLM25JR

Do we really need yet another JAKi? COURAGE-RA RCT phIII JAK1-selective Zemprocitinib RA bDMARDs IR Primary endpoint ACR20 at wk24 79.1% vs 39.7% PBO (p<0.0001) wk24 ACR50: 55.8% vs 22.0% wk 24 DAS28-CRP ≤3.2: 67.0% vs 23.4% No new safety signal Looks very similar to other https://t.co/b0RMBWl4Xx

Low-dose blinatumomab in multidrug-resistant RA 15 pts 96h cycles CD3×CD19 T-cell engager DAS28-CRP: 4.8 → 2.4 3 mo ACR20 100% ACR50 73% ACR70 53% DAS28 remission 33% But... only transient efficacy with 93% relapse after stopping treatment Authors highlight response to https://t.co/GCS6774tJt

#EULAR2026 OP0221 Can we refine response measure in #lupusnephritis RCT? Asia Pacific cohort: construct validity of TRM-SLE definition: 1)RCT entry threshold uPCR >1g/g; 2)clinically meaningful response >50% improvement in UPCR; 3)stricter complete response UPCR<0.2g/g @RheumNow https://t.co/dlErgyFMZP

#OP0223 at #EULAR2026: Not every lupus nephritis patient may need upfront triple therapy. Using EULAR 2025 prognostic factors, triple therapy significantly improved complete renal response only in high-risk patients, supporting more precision-based treatment approach. @RheumNow https://t.co/F8Kn23YjNr

Ivarmacitinib (selective oral JAKi) in active nr-axSpA: This ph3 RCT showed that Ivarmacitinib 4mg significantly improved s/sxs & dse act vs. PBO at wk 12 (39.7% vs 24.8%; P=0.0057) and maintained until wk 24 Interesting. A new JAKi option for axSpA OPO237 @RheumNow #EULAR2026 https://t.co/bxbO8GfegP